- Human（1）
- Mouse（1）
No data
- His Tag（2）
No data
- HEK293（2）
No data
- Unconjugated（2）
No data
- RUO（2）
No data
- No（2）
No data
- 100ug/$350.00
- 1mg/$2500.00
No data
- 100ug/$350.00
- 1mg/$2500.00
No data
| Molecule | Cat. No. | Product Name | Art | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| Legumain | Human Legumain Protein, His Tag (Pro-form) |  Human | HEK293 |  | SDS-PAGE | $350.00 100ug |   | ||
| Legumain | Mouse Legumain Protein, His Tag (Pro-form, HPLC verified) |  Mouse | HEK293 |  | HPLCSDS-PAGE | $350.00 100ug | |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
| Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
| Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
| Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
| Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
| CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
| Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
| Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Keratitis | Details | ||
| CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
| Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
| Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details |
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Nervous System Diseases | Details |
| Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
| Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
| Mouse nerve growth factor (Staidson Biopharma) | Approved | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details |
